• Explore /
  • Poster
  • / Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.

Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.

Abstract Poster

Authors

Sebastian Stintzing

Sebastian Stintzing

Department of Hematology and Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU Munich, Munich, Germany

Sebastian Stintzing , Andreas Jung , Christine Kapaun , Jana Reiche , Dominik Paul Modest , Clemens Albrecht Giessen , Ursula Vehling-Kaiser , Martina Stauch , Holger Hass , Ludwig Fischer von Weikersthal , Thomas Kirchner , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00254137

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3519^)

Abstract #

3519^

Poster Bd #

11

Abstract Disclosures

Similar Posters

First Author: Richard Adams

First Author: Richard A. Adams

First Author: Yu Sunakawa

First Author: Scott Kopetz